University Hospital Heidelberg – Germany
About Dr. Stefan Schonland
Prof. Dr. med. Stefan O. Schönland is an internationally renowned Medical Oncologist and Hematologist with 24+ years of clinical experience and a focused practice in systemic light-chain (AL) amyloidosis, multiple myeloma and rare hematological malignancies. He is co-founder and senior physician of the Amyloidosis Center, Heidelberg University Hospital and Task Force Leader for Amyloidosis at Medical Clinic V (Department of Internal Medicine V — Hematology & Oncology). He is President of the German Society of Amyloid Diseases (DGAK) and President-Elect of the International Society of Amyloidosis. He is widely regarded as one of the leading Medical Oncologist specialists in Heidelberg, Germany for international patients with amyloidosis and rare hematological diseases.
- 24+ years of clinical and research experience in hematology, oncology and amyloidosis
- Senior Physician (Oberarzt) — Department of Internal Medicine V (Hematology / Oncology), Heidelberg University Hospital (UKHD)
- Co-Founder & Co-Lead — Amyloidosis Center Heidelberg, UKHD
- Task Force Leader — Amyloidosis, Medical Clinic V, UKHD
- President — German Society of Amyloid Diseases (DGAK)
- President-Elect — International Society of Amyloidosis (ISA)
Qualifications & Credentials
Medical Degrees
- Studies in Human Medicine (Graduation) — University of Würzburg, Germany, completed 1990
- Doctorate (Dr. med.) — University of Würzburg, Germany
- Habilitation (Venia Legendi) — Ruprecht-Karls University of Heidelberg, Germany
- Professor (Univ.-Prof.) — Heidelberg University, Medical Faculty
Fellowships & Special Training
- Internship — Department of Hematology, Oncology & Rheumatology, Ruprecht-Karls University Heidelberg
- Research Fellowship — Department of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA (Laboratory of Prof. C.M. Weyand and Prof. J.J. Goronzy)
- Continuing professional development in systemic amyloidosis, multiple myeloma and stem-cell transplantation
Certifications & Accreditations
- Board Certification in Internal Medicine — Germany
- Board Certification in Hematology and Oncology — Germany
- Baden-Württemberg State Medical Council — Registered Specialist
- President — German Society of Amyloid Diseases (DGAK)
- President-Elect — International Society of Amyloidosis (ISA)
Areas of Expertise
Major Conditions Treated
- Systemic Light-Chain (AL) Amyloidosis
- Transthyretin (ATTR) Amyloidosis (Hereditary & Wild-Type)
- AA (Secondary) Amyloidosis
- Multiple Myeloma
- Smouldering Multiple Myeloma & MGUS
- Plasma-Cell Disorders
- Waldenström’s Macroglobulinaemia
- Hodgkin and Non-Hodgkin Lymphomas
- Acute & Chronic Leukaemias
- Patients Requiring Autologous Stem-Cell Transplantation
- Selected Solid Tumours (in Multidisciplinary Care)
Sub-specialties
- Systemic Amyloidosis (AL, ATTR, AA): Diagnosis, prognostic staging, organ-response assessment and personalised treatment of systemic amyloidosis — making him a leading Medical Oncologist specialist Heidelberg, Germany for amyloidosis.
- Multiple Myeloma & Plasma-Cell Disorders: Multiple myeloma, smouldering myeloma, MGUS and Waldenström’s macroglobulinaemia; bortezomib-based induction; novel anti-myeloma and anti-amyloid therapies — supporting demand for the best Medical Oncologist doctor in Germany for plasma-cell disorders.
- Stem-Cell Transplantation in Hematological Disease: Autologous and allogeneic hematopoietic stem-cell transplantation in amyloidosis and myeloma.
Advanced Procedures & Treatments
- Comprehensive Amyloidosis Diagnostics (Biopsy, Mass Spectrometry, Genetic Testing)
- Cardiac Amyloidosis Imaging (DPD Scintigraphy, Cardiac MRI Coordination)
- Bortezomib-Based Induction in AL Amyloidosis
- Daratumumab-Based Therapy in AL Amyloidosis & Myeloma
- CAR-T Cell Therapy Coordination (Multiple Myeloma)
- Autologous Hematopoietic Stem-Cell Transplantation
- Allogeneic Hematopoietic Stem-Cell Transplantation (Selected)
- Targeted Therapy & Novel Anti-Amyloid Agents
- Multidisciplinary Tumour / Amyloidosis Board
- Clinical Trials in Amyloidosis & Myeloma
List of Disease and Treatment for which Dr. Stefan Schonland can be consulted
Professional Experience
Current Affiliation
- Senior Physician (Oberarzt), Department of Internal Medicine V — Hematology / Oncology, Heidelberg University Hospital (UKHD), Im Neuenheimer Feld 410, 69120 Heidelberg (Present)
- Co-Founder & Co-Lead — Amyloidosis Center Heidelberg, UKHD (Present)
- Task Force Leader — Amyloidosis, Medical Clinic V, UKHD (Present)
- Professor of Medicine — Heidelberg University, Medical Faculty (Present)
Past Affiliations
- Mayo Clinic, Rochester, Minnesota, USA — Research Fellow, Department of Rheumatology (Lab of Prof. C.M. Weyand and Prof. J.J. Goronzy)
- Ruprecht-Karls University Heidelberg — Internship in Hematology, Oncology & Rheumatology
- University of Würzburg, Germany — Medical Studies and Doctorate, completed 1990
Academic & Research Roles
- Univ.-Prof. of Medicine — Medical Faculty Heidelberg
- President — German Society of Amyloid Diseases (DGAK)
- President-Elect — International Society of Amyloidosis (ISA)
- Active speaker at international amyloidosis, hematology and myeloma congresses (ASH, EHA, ISA, IMS)
- Active mentor for clinician-scientists and PhD candidates at UKHD
Key Achievements
- Co-Founder of the Amyloidosis Center Heidelberg — one of Europe’s leading amyloidosis referral centres
- President of the German Society of Amyloid Diseases (DGAK)
- President-Elect of the International Society of Amyloidosis (ISA)
- Multiple high-impact peer-reviewed publications on AL amyloidosis prognosis, staging and treatment
- Senior author / co-investigator of the multicentre HOVON 104 trial on bortezomib-based induction followed by stem-cell transplantation in light-chain amyloidosis
Awards & Recognitions
National & International Awards
- President — German Society of Amyloid Diseases (DGAK)
- President-Elect — International Society of Amyloidosis (ISA)
Professional Memberships
- German Society of Amyloid Diseases (DGAK) — President
- International Society of Amyloidosis (ISA) — President-Elect
- German Society for Hematology and Medical Oncology (DGHO)
- European Hematology Association (EHA)
- American Society of Hematology (ASH)
- International Myeloma Society (IMS)
Research & Publications
Published Papers (Selected)
- Dittrich T, Kimmich C, Hegenbart U, Schönland SO. Prognosis and Staging of AL Amyloidosis. Acta Haematologica. 2020;143(4):388–400.
- Schönland SO, et al. Prognostic Value of Novel Imaging Parameters Derived from Standard Cardiovascular Magnetic Resonance in High-Risk Patients with Systemic Light-Chain Amyloidosis.
- Schönland SO, et al. New Sequence Variants in Patients Affected by Amyloidosis Show Transthyretin Instability by Isoelectric Focusing.
- Schönland SO, et al. Bortezomib-Based Induction Followed by Stem-Cell Transplantation in Light-Chain Amyloidosis: Results of the Multicenter HOVON 104 Trial.
- Multiple high-impact publications in Acta Haematologica, Blood, Leukemia, Haematologica and the Journal of Clinical Oncology on AL amyloidosis, ATTR amyloidosis and multiple myeloma.
Ongoing Research & Clinical Interests
- Systemic AL and ATTR amyloidosis — diagnosis, prognosis and novel therapies
- Multiple myeloma and plasma-cell disorders
- Bortezomib- and daratumumab-based regimens in amyloidosis
- Anti-amyloid antibody therapy and amyloid-fibril-targeted therapy
- Cardiac amyloidosis imaging and biomarkers
- Stem-cell transplantation in amyloidosis
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (EUR) | Estimated Cost (USD) |
|---|---|---|
| Hematology / Amyloidosis Consultation | €350 – €700 | $380 – $760 |
| Comprehensive Amyloidosis Diagnostic Workup | €3,500 – €8,000 | $3,800 – $8,700 |
| Multidisciplinary Amyloidosis / Tumour Board Review | €700 – €1,800 | $760 – $1,960 |
| Cardiac Amyloidosis Imaging Package | €1,500 – €4,000 | $1,630 – $4,350 |
| Bortezomib-Based Induction (per cycle) | €3,000 – €8,000 | $3,260 – $8,700 |
| Daratumumab-Based Therapy (per month) | €6,000 – €15,000 | $6,500 – $16,300 |
| Autologous Stem-Cell Transplantation | €80,000 – €130,000 | $87,000 – $141,000 |
| Allogeneic Stem-Cell Transplantation | €150,000 – €250,000 | $163,000 – $272,000 |
| CAR-T Cell Therapy (Multiple Myeloma, per course) | €280,000 – €350,000 | $304,000 – $380,000 |
| Inpatient Hematology Stay (per day) | €800 – €1,800 | $870 – $1,960 |
*Indicative estimates only. Actual costs subject to hospital pricing, case complexity, and insurance. Contact Cancer Rounds for a personalised quote.
Frequently Asked Questions
1. What advanced technologies does Prof. Dr. med. Stefan O. Schönland use in Medical Oncologist treatment?
Prof. Dr. med. Stefan O. Schönland employs the latest evidence-based tools and minimally invasive techniques relevant to Medical Oncologist. Virtual consultations and remote second opinions are also available to international patients. Contact Cancer Rounds for a detailed technology overview specific to your case.
2. What conditions does Prof. Dr. med. Stefan O. Schönland specialize in treating?
Prof. Dr. med. Stefan O. Schönland is a specialist in Medical Oncologist, treating a broad spectrum of conditions in this field — including both common presentations and complex, rare cases. International patients seek treatment for conditions requiring expert Medical Oncologist care in Heidelberg, Germany.
3. How do I book an appointment with Prof. Dr. med. Stefan O. Schönland?
Appointments with Prof. Dr. med. Stefan O. Schönland can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Prof. Dr. med. Stefan O. Schönland?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Prof. Dr. med. Stefan O. Schönland, including medical visa invitation letters, airport transfers, and local accommodation coordination.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation, financial counselling, and pre-travel virtual consultations to review medical records before arrival.
6. Does Prof. Dr. med. Stefan O. Schönland offer second opinions for Medical Oncologist cases?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with an expert Medical Oncologist specialist in Heidelberg, Germany.
